Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome. (October 2021)

• Record Type: Journal Article
• Authors: Iselin, Christoph; Chang, Yun-Tsan; Schlaepfer-Eberle, Tanja; Fassnacht, Christina; Dimitriou, Florentia; Nägeli, Mirjam; Pascolo, Steve; Hötzenecker, Wolfram; Bobrowicz, Malgorzata; Guenova, Emmanuella
• Is Part Of: European journal of cancer. Volume 156(2021)Supplement 1
• Page Start: S7
• Publication Date: 2021-10
• Subjects: Cutaneous T cell lymphoma -- Sézary syndrome -- biomarker -- cellular cytotoxicity -- extracorporeal photophoresis -- mycosis fungoides -- treatment response; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(21)00639-0
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract : Sézary syndrome (SS) is a rare, leukemic type of cutaneous T-cell lymphoma (CTCL), for which extracorporeal photopheresis (ECP) is a first-line therapy. Reliable biomarkers to objectively monitor the response to ECP in patients with SS are missing. We examined the quantitative and qualitative impact of ECP on natural killer (NK) cell activity in SS patients, and especially their functional ability for antibody-dependent cell-mediated cytotoxicity (ADCC). Further, we addressed the question whether the magnitude of the effect on ADCC can be associated with the anti-cancer efficacy of ECP in SS patients. We assessed numbers of NK cells, ADCC activity, and treatment response based on blood tumor staging in a cohort of 13 SS patients (8 women, 5 men) treated with ECP as a first-line therapy. Blood samples were collected before treatment start and after an average of 9 months of uninterrupted ECP treatment. NK cell numbers were reduced in SS patients compared to healthy individuals and showed a tendency of recovery after long-term ECP treatment, independent of the clinical response to treatment. Patients with marginal increase (≤1.5 AU-fold) or lack of increase in ADCC activity failed to respond clinically to treatment, while patients with an increased ADCC activity showed a reduction in blood tumor burden. NK-mediated ADCC is selectively enhanced and might be a mechanism underlying the effect of ECP while in addition it can possibly serve as a reliable biomarker to objectively monitor response to ECP in patients with SS.